317: VC struggles, drug pricing negotiations,...

How has the National Institutes of Health been spending its budget? Why are biotech investors feeling gloomy? And what is the most quintessential Boston movie? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We bring on STAT repo ...  عرض المزيد

On this week’s episode of "The Readout LOUD": Why have so many Americans lost trust in science? And how have our policy leaders fueled that mistrust? We speak to STAT’s new trust-in-science reporter Nicholas Florko about the impact of Americans’ growing skepticism of science. You ...  عرض المزيد

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” i ...  عرض المزيد

Earnings are filtering in, and companies are seeing a tale of two very different consumers. The group raising concerns about their customer base, and the names not seeing any slowdown. Plus Novo and Eli Lilly nearing a deal with the White house to lower obesity drug prices. Wh ...

Episode 65: Neal and Toby discuss the increasing buzz around potent weight loss drugs with Pfizer's oral version and Ozempic's anti-addiction side effects. Then, Showtime merges with Paramount+, Max absorbs Discovery+, and Disney+ wants to include Hulu. Are we entering the age of ...  عرض المزيد

We’re following 2 big stories today: CPI & AI. August’s data showed inflation up 3.7% year-over-year. That was hotter than July, but can be blamed on gas prices. Are we really past the inflation threat? We’ll discuss.

Plus, Elon Musk, Mark Zuckerberg and Bill gates are m ...